Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 16 peer-reviewed journal articles Updated

Standard of Care: Treating EGPA with Precision

At a Glance

EGPA treatment focuses on controlling inflammation and reducing long-term steroid use. Therapy depends on disease severity, often starting with prednisone and adding targeted biologics like mepolizumab or immunosuppressants like rituximab to manage symptoms and maintain remission safely.

Deciding on a treatment plan for EGPA is a process of balancing two goals: bringing the active inflammation under control as quickly as possible and minimizing the long-term side effects of medications. According to the 2021 ACR/VF guidelines, your treatment path depends heavily on whether your condition is classified as severe (organ-threatening) or non-severe, which is often determined by the Five-Factor Score [1][2].

Foundational Therapy: Glucocorticoids

Glucocorticoids (such as Prednisone) are the “first responders” of EGPA treatment. They work rapidly to shut down eosinophil production and vessel inflammation [1]. While they are highly effective, long-term use at high doses can cause significant side effects, including bone thinning, weight gain, and mood changes [3][4]. The goal of all other medications is to act as steroid-sparing agents, allowing you to reduce your prednisone dose safely [1][5].

Targeted Biologics and Immunosuppressants

Mepolizumab (Nucala)

This is a biologic therapy that specifically blocks the signal (IL-5) that tells your body to produce eosinophils [6].

  • Best for: Non-severe disease or for patients who cannot lower their steroid dose [1][7].
  • Benefits: Increases remission duration and lowers oral steroid needs [6][8].
  • Side Effects & Safety: Generally well-tolerated, but can cause headaches, back pain, and injection site reactions (redness/swelling). It may also increase susceptibility to certain infections like herpes zoster (shingles) [6][9].

Cyclophosphamide

This is a potent, traditional immunosuppressant used to “induce remission” (stop the initial fire) in severe, life-threatening cases [10][11].

  • Best for: Highly active, organ-threatening disease [12].
  • Side Effects & Safety: Because it is powerful, it carries risks such as severely lowered white blood cell counts, increased infection risk, bladder toxicity, and fertility issues. It is usually only used for a few months [11].

Rituximab (Rituxan)

This is another biologic that targets B-cells, which are part of the immune system that produces ANCA antibodies [13][14].

  • Best for: Severe disease, particularly in patients who are ANCA-positive or have significant nerve/kidney involvement [15][16].
  • Side Effects & Safety: Can cause infusion reactions (fever, chills, blood pressure changes during the IV drip). It significantly lowers your body’s ability to make new antibodies, leading to a high risk of respiratory infections [15][13].

Living Safely on Immunosuppressants

Because EGPA treatments suppress your immune system, you must adopt daily habits to protect yourself from infections [11][5]:

  • Masking: Consider wearing high-quality masks (N95/KN95) in crowded indoor spaces during respiratory virus seasons.
  • Hand Hygiene: Wash hands frequently and carry sanitizer.
  • Vaccines: Discuss all vaccines with your doctor. You will likely need to avoid live vaccines (like the MMR or nasal flu spray) while on immunosuppressants, but should stay up-to-date on non-live vaccines (like flu shots, pneumonia, and COVID-19 boosters) [15].

Common questions in this guide

How do doctors decide if my EGPA is severe or non-severe?
Doctors often use a tool called the Five-Factor Score to assess organ involvement and determine the severity of your EGPA. This score helps guide whether you need aggressive immunosuppressants or more targeted therapies.
Why are steroids like prednisone used for EGPA?
Glucocorticoids act as first responders to rapidly reduce vessel inflammation and stop eosinophil production. However, because long-term use can cause significant side effects, doctors aim to lower your dose safely over time by adding other steroid-sparing medications.
What is mepolizumab (Nucala) and how does it help treat EGPA?
Mepolizumab is a targeted biologic therapy that blocks the signal telling your body to make eosinophils. It is commonly used for non-severe disease to help increase the duration of remission and reduce your dependence on oral steroids.
When is rituximab recommended for EGPA treatment?
Rituximab is typically prescribed for severe, organ-threatening EGPA, especially in patients who are ANCA-positive or have significant nerve or kidney involvement. It works by targeting the B-cells that produce harmful antibodies.
Can I get vaccines while taking EGPA immunosuppressant medications?
You should avoid live vaccines, like the nasal flu spray or MMR, while taking immunosuppressants because your immune system is compromised. However, it is highly recommended to stay up-to-date on non-live vaccines like the flu shot, pneumonia vaccine, and COVID-19 boosters.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my Five-Factor Score (FFS) or other assessments, do you classify my EGPA as 'severe' or 'non-severe'?
  2. 2.Is my daily prednisone dose appropriate for my current phase of treatment, and when can we begin the 'tapering' process?
  3. 3.Am I a candidate for mepolizumab (Nucala)? How might it help reduce my dependence on oral steroids?
  4. 4.Given my ANCA status and specific symptoms, would you recommend rituximab or cyclophosphamide?
  5. 5.What are the specific side effects I should watch for with the immunosuppressants you've prescribed, and should I avoid certain vaccines?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (16)
  1. 1

    2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

    Chung SA, Langford CA, Maz M, et al.

    Arthritis care & research 2021; (73(8)):1088-1105 doi:10.1002/acr.24634.

    PMID: 34235880
  2. 2

    2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

    Chung SA, Langford CA, Maz M, et al.

    Arthritis & rheumatology (Hoboken, N.J.) 2021; (73(8)):1366-1383 doi:10.1002/art.41773.

    PMID: 34235894
  3. 3

    Updates for the treatment of EGPA.

    Raffray L, Guillevin L

    Presse medicale (Paris, France : 1983) 2020; (49(3)):104036 doi:10.1016/j.lpm.2020.104036.

    PMID: 32652104
  4. 4

    [Eosinophilic granulomatosis with polyangiitis].

    Romero Gómez C, Hernández Negrín H, Ayala Gutiérrez MDM

    Medicina clinica 2023; (160(7)):310-317 doi:10.1016/j.medcli.2023.01.003.

    PMID: 36774291
  5. 5

    Real-world safety and effectiveness of mepolizumab for patients with eosinophilic granulomatosis with polyangiitis in Japan: Long-term observation of the MARS study.

    Ishii T, Kunishige H, Kobayashi T, et al.

    Modern rheumatology 2025; (35(3)):505-515 doi:10.1093/mr/roae100.

    PMID: 39508562
  6. 6

    Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis.

    Wechsler ME, Akuthota P, Jayne D, et al.

    The New England journal of medicine 2017; (376(20)):1921-1932 doi:10.1056/NEJMoa1702079.

    PMID: 28514601
  7. 7

    Real-world mepolizumab treatment in eosinophilic granulomatosis with polyangiitis reduces disease burden in the United States.

    Mathur SK, Silver J, MacKnight SD, et al.

    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2025; (134(3)):341-350.e2 doi:10.1016/j.anai.2024.11.004.

    PMID: 39549986
  8. 8

    Efficacy and Safety of Mepolizumab in Patients With Eosinophilic Granulomatosis With Polyangiitis: A Single-Center Experience.

    Abuzakouk M, Isse S, Wechsler M, et al.

    Cureus 2024; (16(8)):e68282 doi:10.7759/cureus.68282.

    PMID: 39350857
  9. 9

    Real-world safety and effectiveness of mepolizumab for patients with eosinophilic granulomatosis with polyangiitis in Japan: A subgroup analysis of the MARS study.

    Ishii T, Kunishige H, Yoshida M, et al.

    Modern rheumatology 2026; (36(2)):272-281 doi:10.1093/mr/roaf096.

    PMID: 41092276
  10. 10

    EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update.

    Hellmich B, Sanchez-Alamo B, Schirmer JH, et al.

    Annals of the rheumatic diseases 2024; (83(1)):30-47 doi:10.1136/ard-2022-223764.

    PMID: 36927642
  11. 11

    Eosinophilic Granulomatosis with Polyangiitis Presenting with Central Retinal Artery Occlusion During Treatment with Anti-interleukin-5 Receptor Monoclonal Antibody.

    Nishiyama H, Tajiri T, Yamabe T, et al.

    Internal medicine (Tokyo, Japan) 2021; (60(22)):3631-3634 doi:10.2169/internalmedicine.7027-21.

    PMID: 34092731
  12. 12

    Glomerulonephritis and Interstitial Nephritis Originating from Vasculitis of the Interlobular Arteries of the Kidney in a Patient with Eosinophilic Granulomatosis with Polyangiitis.

    Nawata T, Shibuya M, Takeshita Y, et al.

    Case reports in rheumatology 2022; (2022()):9606981 doi:10.1155/2022/9606981.

    PMID: 36212163
  13. 13

    Hypertrophic Pachymeningitis Development in Eosinophilic Granulomatosis with Polyangiitis at Relapse of Disease: A Case-Based Review.

    Kiyohara M, Shirai T, Nishiyama S, et al.

    The Tohoku journal of experimental medicine 2022; (256(3)):241-247 doi:10.1620/tjem.256.241.

    PMID: 35321968
  14. 14

    Refractory diffuse alveolar hemorrhage caused by eosinophilic granulomatosis with polyangiitis in the absence of elevated biomarkers treated successfully by rituximab and mepolizumab: A case report.

    Shiroshita A, Nakashima K, Motojima S, Aoshima M

    Respiratory medicine case reports 2019; (26()):112-114 doi:10.1016/j.rmcr.2018.12.010.

    PMID: 30603598
  15. 15

    Granulomatosis with polyangiitis (Wegener's).

    Puéchal X

    Joint bone spine 2020; (87(6)):572-578 doi:10.1016/j.jbspin.2020.06.005.

    PMID: 32562697
  16. 16

    Eosinophilic granulomatosis with polyangiitis: sequential use of mepolizumab following rituximab for inadequate asthma control despite vasculitis remission.

    Cremonezi Lammoglia B, De Aguiar Trevise L, Paslar Leal T, et al.

    Reumatismo 2023; (75(4)) doi:10.4081/reumatismo.2023.1588.

    PMID: 38115776

This page explains EGPA treatment options for educational purposes only. Always consult your doctor or specialist to determine the safest and most effective treatment plan for your specific condition.

Get notified when new evidence is published on Eosinophilic granulomatosis with polyangiitis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.